LOG IN OR SIGN UP TO "MY Eu2P"Quality Indicators
Key figures (Sep 2011 - Oct 2022)
Read more
Read more
Read more
Some former students' testimonials
The course is structured into bite sizes and I honestly don’t know where my 4 years went. The pace was just right for me and I highly recommend this online master. This programme is also a fantastic opportunity to network with colleagues in the industry whether it is pharmaceutical, academics, regulators etc.
Full quote
The most import aspect about the program is that it did not interrupt my work schedule and many aspects were practical to be related and implemented in my routine activities as a regulator.
Great Job Eu2P!! You made my career.
Full quote
I enjoyed the flexibility and adaptability of the training considering I had to combine this with full-time employment, the administrators were always ready to provide support and assistance when required.
Full quote
Overall, it was a fantastic journey as I had really nice supervisors and the Eu2P office to answer to my every query.
Full quote
I highly recommend it to anyone interested in pursuing a career in the field.
Full quote
It is one of the very demanding and stringent courses I have done and that exemplifies the emphasis that the organization places on quality thereby ensuring that they develop core competency to the highest in professionals taking the course.
Full quote
Organisations trusting us for staff competency development
Education Excellence
- Job-oriented courses
- Made flexible
- With genuine academic quality
- Real-life practices inputs from insiders such as the regulatory and industry members of the Eu2P consortium and from international guest experts invited to share experience and interact with students
- Course compliance with the core competencies and knowledge requirements such as WHO-ISoP requirements for pharmacovigilance and ISPE requirements for pharmacoepidemiology and with the imi-train competency profiles in Drug Safety Sciences
- Inclusion of last research and methodologies advances in collaboration with the IMI PROTECT stakeholders
- The full online courses approach to ease professional study-time management has been awarded a trophy for higher education innovation (Educatec-Educatice 2012)
- Modular and time flexible courses comply with lifelong learning and continuing professional development as described by the LifeTrain initiative
- Academic standards and quality of the programme are ensured by the Eu2P Executive Board including academic representatives of the 6 Eu2P degree awarding universities
- Compliance with main quality items of ENQA's report on "Standards and Guidelines for Quality Assurance in the European Higher Education Area"
- Cross quality review of assessments between Eu2P academic partners
- Independent external examination of programme assessments and equity
Recommendations & collaborations
Eu2P training programme is recommended by the ENCePP as important in building future capacity in the European Union to undertake high quality, scientifically independent research
.
Read more
The North America chapter from the International Society of Pharmacovigilance (NASoP) has collaborated with Eu2P to build a new education program tailored to North American medicines-stakeholders, the American Program in Pharmacovigilance Am2P.
Read more
IMI PROTECT project and Eu2P fostered collaboration in postgraduate training and exchange of trainees between pharmacovigilance and pharmacoepidemiology centres. PROTECT has also provided pharmacoepidemiological research findings and new methodology inputs for Eu2P teaching materials and programmes.
Read more
Eu2P training programme has been awarded a PharmaTrain Centre Recognition following a quality assessment of its Master Education and Training programme by The PharmaTrain Federation.
Read more
IMI EMTRAIN's On-course®, the European portal of biomedical postgraduate education and training resources has indexed Eu2P courses and provides a Eu2P course filter in its Advanced Search feature.
Read more
IMI SafeSciMET has collaborated with Eu2P to adapt course modules into a blended learning format on the Eu2P eLearning platform under the collaborative framework of the imi-train project.
Read more
IMI European platform for education and training in the medical, biomedical and pharmaceutical sciences, imi-train, promotes Eu2P academic postgraduate programmes as well as CPD training in pharmacovigilance and pharmacoepidemiology.
Read more
Publications & media highlights
- Current career situations of Chinese pharmacovigilance professionals working for pharmaceutical companies: an exploratory survey.
Tang et al.
BMC Health Serv Res (2023). - Training Opportunities for a Career in the Pharmaceutical and Biomedical Industry.
Thomas, J.R.
In Career Options in the Pharmaceutical and Biomedical Industry. Springer, Cham.(2023). - European Regulatory Science and Regulatory Science Expert Training Project .
Shin et al.
Korean Journal of Clinical Pharmacy (2021). - A Multidisciplinary Approach in Pharmacovigilance Awareness: ISoP Egypt Chapter's MedSafetyWeek Experience.
Rostom et al.
Drug Safety (2021). - A systematic review on learning outcomes of pharmacovigilance issues: Undergraduates of pharmacy.
Pires C.
International Journal of Educational Research (2021). - Global Pharmacovigilance, challenges, and future considerations: West globe and East globe.
Gadhade JS, Hiray RS.
Journal of Pharmacovigilance and Drug Research (2021). - Drug safety academic programme expands to North America.
Innovative Medicines Initiative (2021). - For research projects to leave a legacy, long-term vision is vital.
Innovative Medicines Initiative (2021). - An Update of the North American Chapter of the International Society of Pharmacovigilance (NASoP).
Gossell-Williams, M. et al.
Drug Safety (2021). - Socio-Economic Impact Report on IMI1 projects.
Centre for Innovation in Regulatory Science (2021). - Chapter 23 - Translational safety medicine.
Ernst et al.
Principles of Translational Science in Medicine (Third Edition 2021). - Harmonizing and improving European education in prescribing: An overview of digital educational resources used in clinical pharmacology and therapeutics.
M. J. Bakkum et al.
British Journal of Clinical Pharmacology (2020). - Pharmacovigilance: Challenges in Getting From Here to There.
P. Beninger
Clinical Therapeutics (Dec. 2018). - Pharmacovigilance: Our experience in Aden.
M. Alshakka and W. Badulla
World Journal of Pharmaceutical Sciences (Oct. 2018). - A Review of the Contributions of Cross-discipline Collaborative European IMI/EFPIA Research Projects to the Development of Replacement, Reduction and Refinement Strategies.
S. Wolfensohn
Alternatives to Laboratory Animals (May 2018). - Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action.
A. Radecka, L. Loughlin, M. Foy, M. Viana de Ferraz Guimaraes, V. Macolic Sarinic, M. Dimov Di Giusti, M. Lesicar, S. Straus, D. Montero, J. Pallos, J. Ivanovic, J. Raine
Drug Saf (2018). - What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects.
R. van Eekeren, L. Rolfes, A.S. Koster, L. Magro, G. Parthasarathi, H. Al Ramimmy, T. Schutte, D. Tanaka, E. van Puijenbroek, L. Härmark
Drug Saf (2018). - 'All this wouldn’t have been possible without IMI' - an interview with Eu2P project coordinators.
IMI JU in Success stories from projects, 01 February 2018. - Carrying the torch for medical innovation.
IMI JU in IMI Results and Impact, 06 Octobre 2017. - Risk Communication in a Pharmacovigilance Environment.
P. Beninger
Clinical Therapeutics. 39, no. 4 (April 2017): 672–74. - An Introduction to Pharmacovigilance, 2nd Edition.
P. Waller, and M. Harrison-Woolrych
Wiley-Blackwell, April 2017. - Practical Implementation in Six Member States.
M. Kaeding, J. Schmälter, C. Klika. in Pharmacovigilance in the European Union : Practical Implementation across Member States, edited by Wiesbaden: Springer, February 2017. - البرنامج الأوروبي في اليقظة الدوائية: درجة الماجستير في اليقظة الدوائية عن بعد [European programme in pharmacovigilance: distant pharmacovigilance Master programme]
هاجر علي [Hager Ali]
Egypt Scholars blog May, 2017 - From Face-to-Face training to blended learning in the postgraduate program SafeSciMET - a case study.
J.C. Vos, S. Dragovic, M. Jochimsen, J. Dirach, H. Foth, J. Wiese, O.J. Bjerrum
Eur. J. Pharm. Sci., 01 January 2017. - Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data.
O. Yildirim, M. Gottwald, P. Schüler and M.C. Michel
Front. Pharmacol., 06 December 2016. - Job and Career Opportunities in the Pharmaceutical Sector.
J.R. Thomas, C. van Schravendijk, L. Smit and L. Saso.
In Special Topics in Drug Discovery, edited by T. Chen and S.C. Chai, November 2016. - Elaboration et évaluation d’un site d’e-learning pour l’apprentissage de la recherche en médecine générale.
N. De Chanaud.
Thèse de Médecine Générale, 27 septembre 2016. - How can an adaptive training programme support change in organisational strategy?
K. Palin
Intrinsic Activity, 2016; 4 (Suppl. 1): A4.1 - Essential learnings: How do I begin...?
S. Mt-Isa
benefit-risk assessment, the blog around structured decision making in medicine, June, 2016 - Shaping Europe's Vision for Personalised Medicine.
The PerMed SRIA (Strategic Research and Innovation Agenda), Jul. 2015. - Structured Benefit–risk Assessment: A Review of Key Publications and Initiatives on Frameworks and Methodologies.
S. Mt-Isa, M. Ouwens, V. Robert, M. Gebel, A. Schacht, and I. Hirsch.
Pharmaceutical Statistics, May 2015. - European Initiatives for Better Training in Medicines Development.
M. Hardman
Journal of Medicines Development Sciences 1, no. 1 (May 2015). - Guide de Conception de Formation Ouverte et à Distance (FOAD) Dans Le Monde de La Santé.
Haute Autorité de santé, Apr. 2015. - The Innovative Medicines Initiative: an engine for regulatory science.
M. Goldman, N. Seigneuret, H.G. Eichler
Nat Rev Drug Discov. 2015 Jan;14(1):1-2. - Chapter 6 - How Can the Innovative Medicines Initiative Help to Make Medicines Development More Efficient?
M. Gottwald
In Re-Engineering Clinical Trials, 55–63. Elsevier - Academic Press, Jan. 2015. - Teaching Pharmacovigilance: The WHO-ISoP Core Elements of a Comprehensive Modular Curriculum.
J. Beckmann, U. Hagemann, P. Bahri, A. Bate, I.W. Boyd, G.J. Dal Pan, B.D. Edwards, et al.
Drug Safety, Aug. 2014, 1–17. - Practical Experience in Teaching Pharmacovigilance.
S. Evans, and I. Douglas
In Mann's Pharmacovigilance, 805–6. John Wiley & Sons, Ltd, Apr. 2014. - Eu2P: The First European Online Public–Private Joint Training Program in Pharmacovigilance and Pharmacoepidemiology.
K. Palin, C. Bataille, S. Liège, R. Schimmer, and A. Fourrier-Réglat
In Mann's Pharmacovigilance, 785–92. John Wiley & Sons, Ltd, Apr. 2014. - Bordeaux : L'Université Se Met Au Numérique.
Edition 12/13
France 3 Aquitaine. Feb. 2014. - Towards a Single VOICE for European Clinical Pharmacology: Proposals for Future Developments.
J.K. Aronson and G. Velo.
European Journal of Clinical Pharmacology 69, no. 11 (Nov. 2013): 1981–84. - La Formation à Distance 'Made in Aquitaine' Qui Intéresse Harvard.
Journal l'Aquitaine, journal d'information du Conseil Régional d'Aquitaine, Sep. 2013. - Prescrire juste, plutôt que juste prescrire.
M. Molimard, M.-C. Perault-Pochat, C. Funck-Brentano, M. Bardou, R. Bordet, and J.-L. Montastruc.
Le Monde.fr, Apr. 2013. - Regulatory Science: Researchers in the Pipeline.
A. Dance.
Nature 496, no. 7445 (Apr. 2013): 387–89. - Opening Industry-Academic Partnerships.
C. Tachibana.
Science, Apr. 2013. - Background Paper 7.4 Pharmacogenetics and Stratified Medicine.
S.J.H. Vijverberg, A.-H. Maitland-van der Zee.
From Priority Medicines for Europe and the World Project "A Public Health Approach to Innovation" by the World Health Organization, Mar. 2013. - Enseignement : Bordeaux Segalen Tient La Distance.
H. R.-V.
Sud-Ouest Feb. 2013. - Continuing Medical Education and Professional Development in the European Union.
H. Silva, F.R. Bühler, B. Maillet, H. Maisonneuve, L.A. Miller, A. Negri, and P.D. Stonier.
Pharmaceutical Medicine 26, no. 4 (Dec. 2012): 223–33. - Better Comms in Meds.
K. Palin, C. Bataille, S. Liège, E. Swain, A. Fourrier-Réglat, and R. Schimmer.
Public Service Review: Health and Social Care, no. 34 (Dec. 2012): 71.
- TV report on Eu2P programme
Emission Modes d'Emplois.
TV7 Bordeaux, Nov. 2012. - Pharmacovigilance Medical Writing: A Good Practice Guide
J. Orleans-Lindsay.
Wiley-Blackwell, July 2012 - Conference Scene: 5th Anniversary Meeting of the European Research Network Pharmacogenetics/Pharmacogenomics.
J.C. Fox, A. Daly, I. Cascorbi, A. Alfirevic, H. Linden, and A.-H. Maitland-van der Zee
Pharmacogenomics Vol. 13, No. 7 (May 2012): 747-749. - European Initiative towards Quality Standards in Education and Training for Discovery, Development and Use of Medicines.
H. Klech, C. Brooksbank, S. Price, P. Verpillat, F.R. Bühler, D. Dubois, N. Haider, et al.
European Journal of Pharmaceutical Sciences 45, no. 5 (Apr. 2012): 515–20. - The Innovative Medicines Initiative: A European Response to the Innovation Challenge.
M. Goldman.
Clinical Pharmacology & Therapeutics 91, no. 3 (Mar. 2012): 418–25. - Cobert's Manual of Drug Safety and Pharmacovigilance.
B. Cobert.
Jones & Bartlett Learning 2011.
This programme is ideal for those working full time and for those that have to travel for work. I was very impressed with the platform and opportunity to work at my own pace with detailed learning materials and access to course tutors just a click away. The course is structured into bite sizes and I honestly don’t know where my 4 years went. The pace was just right for me and I highly recommend this online master. This programme is also a fantastic opportunity to network with colleagues in the industry whether it is pharmaceutical, academics, regulators etc. I learnt so much on this programme and it has really helped me to broaden my understanding of PV and pharmacoepidemiology.
As a person who had a quest to have an in-depth understanding of Pharmacovigilance, Eu2P gave me an opportunity to understand the concepts from a wider perspective. I consider myself now to have a balanced understanding, enabling me to make decisions and policies at work with all stakeholder perspective in mind. The program is worth the time and investment for anyone who wants to advance in appropriate medicine use. The most import aspect about the program is that it did not interrupt my work schedule and many aspects were practical to be related and implemented in my routine activities as a regulator. Great Job Eu2P!! You made my career.
My Eu2P training was a wonderful learning experience because it is a practical reflection of scenarios that occur within the pharmaceutical industry. Before attending the training, I already had some practical knowledge which I was able to improve on with the complementary theoretical approach of the training. The training was a hybrid of academics and practical experience as many of the lecturers are accomplished speakers with backgrounds in the Pharma industry, Health authorities and academics. I enjoyed the flexibility and adaptability of the training considering I had to combine this with full-time employment, the administrators were always ready to provide support and assistance when required. The training has inspired me to consider enrolling more advanced training with the Eu2P programme.
The Eu2P programme is highly recommended to busy clinicians and University lecturers as it creates an opportunity to obtain a certificate from highly rated Universities whilst practising overseas. I found the course content quite diverse and relevant to my doctoral research. Furthermore, the inclusion of mobility as a requirement in the program enabled networking with others in the field. Again, the online format helped me interact with my thesis supervisors and perform the course work from my home country and without interfering too much with my regular work. Overall, it was a fantastic journey as I had really nice supervisors and the Eu2P office to answer to my every query.
The Eu2P master’s degree program offers a multidisciplinary and holistic approach to Pharmacoepidemiology and Pharmacovigilance. I highly recommend it to anyone interested in pursuing a career in the field.
Overall, it was a very enriching experience completing the certificate program on benefit-risk assessment in drug development, offered by Eu2P. It is one of the very demanding and stringent courses I have done and that exemplifies the emphasis that the organization places on quality thereby ensuring that they develop core competency to the highest in professionals taking the course. I am sure that if another opportunity comes through my organization, I will definitely consider enrolling in other professional development courses as well, in addition to sharing my positive experiences with my colleagues and professional acquaintances.
